Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.10 Average Price Target from Analysts

Key Points

• Cardiff Oncology has received an average recommendation of "Moderate Buy" from six brokerages, with a consensus price target of $10.10 for the next year.
• Insider trading activity includes Director Gary W. Pace purchasing 15,000 shares at $2.45 per share, increasing his ownership in the company.
• Cardiff Oncology reported a loss of $0.21 EPS for the last quarter, falling short of the estimated loss of $0.19, while their revenue was $0.12 million, slightly exceeding expectations.

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $10.10.

Several research analysts have issued reports on CRDF shares. William Blair reiterated an "outperform" rating on shares of Cardiff Oncology in a report on Wednesday, June 18th. HC Wainwright dropped their target price on shares of Cardiff Oncology from $18.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. LADENBURG THALM/SH SH started coverage on shares of Cardiff Oncology in a report on Tuesday, July 8th. They set a "buy" rating and a $19.00 target price on the stock. Finally, Jefferies Financial Group started coverage on shares of Cardiff Oncology in a report on Tuesday, June 24th. They set a "hold" rating and a $3.50 target price on the stock.

Cardiff Oncology Stock Performance

Cardiff Oncology stock traded up $0.02 during midday trading on Wednesday, hitting $2.10. 862,176 shares of the company's stock were exchanged, compared to its average volume of 1,268,325. Cardiff Oncology has a 12 month low of $2.06 and a 12 month high of $5.64. The firm has a 50-day moving average of $3.10 and a two-hundred day moving average of $3.26. The company has a market cap of $139.71 million, a PE ratio of -2.41 and a beta of 1.29.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Cardiff Oncology had a negative return on equity of 77.94% and a negative net margin of 9,344.14%.The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.11 million. As a group, equities analysts expect that Cardiff Oncology will post -0.99 earnings per share for the current year.

Insider Buying and Selling at Cardiff Oncology

In other news, Director Gary W. Pace purchased 15,000 shares of the stock in a transaction dated Wednesday, July 30th. The shares were acquired at an average cost of $2.45 per share, for a total transaction of $36,750.00. Following the acquisition, the director owned 1,345,676 shares of the company's stock, valued at approximately $3,296,906.20. This represents a 1.13% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.70% of the company's stock.

Institutional Trading of Cardiff Oncology

A number of institutional investors have recently modified their holdings of the company. Blair William & Co. IL raised its position in shares of Cardiff Oncology by 44.1% in the 2nd quarter. Blair William & Co. IL now owns 2,524,118 shares of the company's stock valued at $7,951,000 after purchasing an additional 772,844 shares during the last quarter. Orbimed Advisors LLC purchased a new position in shares of Cardiff Oncology in the 4th quarter valued at approximately $6,677,000. Geode Capital Management LLC raised its position in shares of Cardiff Oncology by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company's stock valued at $4,723,000 after purchasing an additional 104,409 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Cardiff Oncology by 11.8% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,445,000 shares of the company's stock valued at $4,537,000 after purchasing an additional 152,692 shares during the last quarter. Finally, Acorn Capital Advisors LLC purchased a new position in shares of Cardiff Oncology in the 4th quarter valued at approximately $6,260,000. 16.29% of the stock is currently owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.